

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Kevin Jeffrey Barnham, et al.

**Serial No.:** 10/530,137

**Filed:** October 3, 2005

**For:** NEUROLOGICALLY-ACTIVE  
COMPOUNDS



**Examiner:** Unassigned

**Art Unit:** 1624

**Docket:** 18803

**Dated:** January 24, 2007

Mailstop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.


1. U.S. Patent No. 6,369,058 B1, April 9, 2002 to Hussain, et al.;
2. U.S. Patent No. 5,902,810 A, May 11, 1999 to Pfleiderer, et al.;
3. U.S. 2002/0025944 A1, February 28, 2002 to Bush, et al.;
4. Chemical Abstract 45:48030 (& Yakugaku Zasshi (1945), 65, 69)  
See Chem Abs RN410543-30-5;

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mailstop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 24, 2007.

Dated: January 24, 2007

  
Xiaochun Zhu


5. Chemical Abstract 111:194704 (& Tetrahedron Letters (1989), 30 (12), 1529-39);
6. Chemical Abstract 24:53157 (& Journal of the American Chemical Society, 1930, 52, 3974.7);
7. Chemical Abstract 48:46261 (& Journal of the Chemical Society, Abstracts, 1952, 5985-5993);
8. EP 0 290 819 B1, November 17, 1988 to Bioresearch S.p.A.;
9. WO 02/085908 A1, February 29, 2002 to Bush, et al.;
10. WO 03/010146 A1, February 6, 2003 to Neuro3D;
11. WO 03/016309 A1, February 27, 2003 to Merck & Co., Inc.;
12. WO 95/12417 A1, May 11, 1995 to ACEA Pharmaceuticals Inc., et al.;
13. WO 94/24379 A1, September 14, 1995 to Cancer Research Campaign Technology Limited;
14. WO 98/06403, February 19, 1998 to Gerolymatos, S.A.;
15. WO 02/50065 A2, June 27, 2002 to Vertex Pharmaceuticals Inc.;
16. WO 98/47969A1, October 29, 1998 to University of Pittsburgh;
17. WO 96/22990 A1, August 1, 1996, The State of Oregon;
18. Koshimuro K. et al. "The Role of 6R-tetrahydrobiopterin in the nervous system", Progress in Neurobiology 61 (2000), 415-438.

The references were cited in an International Search Report dated January 6, 2004.

Applicants are submitting copies of Reference Nos. 4-18, as required by 37 C.F.R. 1.98 (a)(2)(i) and (ii), together with a copy of the Search Report. The relevance of the above-identified references has been described in the Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,


A handwritten signature in black ink, appearing to read 'Xiaochun Zhu', written in a cursive style.

Xiaochun Zhu

Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza - Ste. 300  
Garden City, New York 11530  
(516) 742-4343  
XZ:bk

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>				ATTY DOCKET NO. <b>18803</b>		APPLICATION NO. <b>10/530,137</b>	
				APPLICANT(S) <b>Kevin Jeffrey Barnham, et al.</b>			
				FILING DATE <b>10/3/2005</b>		GROUP ART UNIT <b>1624</b>	



U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	<b>6,369,058 B1</b>	<b>4/9/2002</b>	<b>Hussein, et al.</b>				
	<b>5,902,810 A</b>	<b>5/11/99</b>	<b>Pfleiderer, et al.</b>				

U.S. PATENT APPLICATION PUBLICATIONS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	<b>2002/0025944 A1</b>	<b>2/20/02</b>	<b>Bush, et al.</b>				

FOREIGN PATENT DOCUMENTS								
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
						YES	NO	
	<b>EP 0 290 819 B1</b>	<b>11/17/88</b>	<b>EPO</b>			<input checked="" type="checkbox"/>		
	<b>WO 02/085908 A1</b>	<b>2/20/02</b>	<b>PCT</b>			<input checked="" type="checkbox"/>		
	<b>WO 03/010146 A1</b>	<b>2/2/03</b>	<b>PCT</b>			<input checked="" type="checkbox"/>		
	<b>WO 03/016309 A1</b>	<b>2/27/03</b>	<b>PCT</b>			<input checked="" type="checkbox"/>		
	<b>WO 95/12417 A1</b>	<b>5/11/95</b>	<b>PCT</b>					

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>			
			<b>Chemical Abstract 45:48030 (&amp; Yakugaku Zasshi (1945), 65, 69 ; Chem Abs RN410543-30-5</b>
			<b>Chemical Abstract 111:194704 (&amp; Tetrahedron Letters (1989), 30 (12), 1529-39)</b>

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>	ATTY DOCKET NO. <b>18803</b>	APPLICATION NO. <b>10/530,137</b>
	<b>Kevin Jeffrey Barnham, et al.</b>	
	FILING <b>10/3/2005</b>	GROUP ART <b>1624 -</b>

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**U.S. PATENT APPLICATION PUBLICATIONS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 94/24379 A1	9/14/95	PCT			✓	
	WO 98/06403	2/19/98	PCT			✓	
	WO 02/50065	6/27/02	PCT			✓	
	WO 98/47969 A1	10/29/88	PCT			✓	
	WO 96/22990 A1	8/1/96	PCT			✓	

**OTHER DOCUMENTS** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

		Chemical Abstract 24:53157 (& Journal of the American Chemical Society, 1930, 52, 3974.7)
		Chemical Abstract 48:46261 (& Journal of the Chemical Society, Abstracts, 1952, 5985-5993).

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>	ATTY DOCKET NO. <b>18803</b>	APPLICATION NO. <b>10/530,137</b>
	<b>Kevin Jeffrey Barnham, et al.</b>	
	FILING <b>10/3/2005</b>	GROUP ART <b>1624</b>

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>			
			Koshimuro K. et al. "The Role of 6R-tetrahydrobiopterin in the nervous system", Progress in Neurobiology 61 (2000), 415-438.


EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
**18803**

In Re Application Of: **Kevin Jeffrey Barnham, et al.**



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/530,137	10/3/2005	Unassigned	23389	1624	4715

Title: **NEUROLOGICALLY ACTIVE COMPOUNDS**

Address to:  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.


**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(e))

Docket No.  
18803

In Re Application of: Kevin Jeffrey Barnham, et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/530,137	10/3/2005	Unassigned	23389	1624	4715

Title: NEUROLOGICALLY ACTIVE COMPOUNDS

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

January 24, 2007

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature of Person Mailing Correspondence

Xiaochun Zhu

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

**\*This certificate may only be used if paying by deposit account.**

\_\_\_\_\_  
Signature

Dated: January 24, 2007

Xiaochun Zhu  
Registration No. 56,311  
Scully, Scott, Murphy & Presser, PC  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
(516) 742-4343

cc: XZ:bk